Contract drugmaker Patheon inked a deal to manufacture Flexion Therapeutics' ($FLXN) top prospect as it moves through clinical development. The treatment, FX006, is an injectable steroid treatment for osteoarthritis pain, and its promise helped Flexion pull off a $60 million IPO last year. Under the latest agreement, Patheon will use its Swindon, U.K., site to manufacture doses of FX006 to support the drug's ongoing Phase III trial. More